Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Strategies & Market Trends : 2026 TeoTwawKi ... 2032 Darkest Interregnum -- Ignore unavailable to you. Want to Upgrade?

To: Snowshoe who wrote (179517)	10/20/2021 6:58:43 PM
From: Snowshoe	Respond to of 219927

Britain secures COVID-19 antivirals from Merck and Pfizer finance.yahoo.com Britain said it had secured 480,000 courses of Merck's molnupiravir, an antiviral pill which can be used in non-hospitalised patients. The drug cut the rate of hospitalization and death by 50% in mild-to-moderately ill patients who had at least one risk factor for the disease, according to trial data released earlier this month. If approved, molnupiravir, which Merck is developing with partner Ridgeback Biotherapeutics, could become the first oral antiviral medication for COVID-19. Pfizer is also racing to develop an easy-to-administer antiviral pill for COVID-19, and last month began a large study of its investigational oral antiviral drug for the prevention of COVID-19 in people exposed to the virus. In the trial, PF-07321332, designed to block the activity of a key enzyme needed for the coronavirus to multiply, will be administered along with a low dose of ritonavir, an older medication widely used in combination treatments for HIV infection. Britain said it had secured 250,000 courses of the PF-07321332/ritonavir antiviral.